2026-07-02

JTO/JitoSOL has $819.9M 24h volume on $1689K liquidity (485x turnover): thin market, elevated slippage

BTC open interest +237.3% — OI surge

ETH open interest -68.2% — OI collapse

SOL open interest +222.7% — OI surge

ETH ETF outflow of $226M — institutional selling

BTC ETF outflow of $2272M — institutional selling

BTC open interest +236.5% — OI surge

ETH open interest +207.0% — OI surge

SOL open interest -56.3% — OI collapse

BTC open interest +241.0% — OI surge

SOL open interest -57.4% — OI collapse

ETH open interest +210.5% — OI surge

ETH ETF outflow of $226M — institutional selling

BTC open interest -70.1% — OI collapse

SOL open interest -58.4% — OI collapse

ETH open interest -67.8% — OI collapse

ETH DEX volume/liquidity ratio elevated (0.50x): on-chain trade volume 0.50x liquidity

SOL DEX volume/liquidity ratio elevated (5.09x): on-chain trade volume 5.09x liquidity

SOL RSI 70.1 — overbought (crossed above 70)

CFTC NATURAL GAS speculators at extreme long: 52-week positioning extreme

CFTC BITCOIN speculators at extreme long: 52-week positioning extreme

Coffee bear 6.8% vs prior close ($324.30 → $302.15)

Coffee volume spike — 2.7× the 20-day average (27,600 vs 10,231 avg)

OSINT: Israeli Threats to Iranian Leaders Spark Tension as Iran Claims Pakistani Escort

CFTC BITCOIN speculators at extreme long: 52-week positioning extreme

CFTC NATURAL GAS speculators at extreme long: 52-week positioning extreme

OSINT: Hassett flags Powell's Fed tenure as unusual

CFTC NATURAL GAS speculators at extreme long: 52-week positioning extreme

CFTC BITCOIN speculators at extreme long: 52-week positioning extreme

OSINT: Solana tops blockchain for tokenized RWAs, $3.4B value hits record

CFTC NATURAL GAS speculators at extreme long: 52-week positioning extreme

CFTC BITCOIN speculators at extreme long: 52-week positioning extreme

OSINT: Trump backs Freedom Fuel Network's price cuts at 25 NE stations

Cotton bull 5.8% vs prior close ($73.28 → $77.52)

Corn bull 4.7% vs prior close ($421.00 → $440.75)

Gold +1.61%: significant gain on the session

Oil -1.46%: significant decline on the session

Phase 3 trial terminated early — ELI A Study in Participants With Rheumatoid Arthritis

Phase 3 trial terminated early — ELI Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty A

Phase 3 trial terminated early — BIOGEN Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improv

Phase 3 trial terminated early — AMGEN Reducing Intracranial atheroSclErosis With Repatha

Phase 3 trial terminated early — Medtronic CORE: Study to Evaluate the Conducted AF-Response-Algorithm in Patients Sufferin

Phase 3 trial terminated early — AbbVie A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line

Phase 3 trial terminated early — Merck A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Comp

Phase 3 trial terminated early — Merck Study Comparing Cubicin With Vancomycin in Treatment of Participants With Compli

Phase 3 trial terminated early — Merck An Investigational Drug Study to Assess Weight Loss in Obese and Overweight Pati

Phase 3 trial terminated early — PFIZER Acute Cough Study In Children

Phase 3 trial terminated early — PFIZER A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer

Phase 3 trial terminated early — ABBOTT Cardiac and Renal Biomarkers in Arthroplasty Surgery

Phase 3 trial terminated early — ABBOTT Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyro

Phase 3 trial terminated early — JOHNSON Transvaginal Tape (TVT) Secur Versus TVT Randomised Controlled Trial (RCT)

Phase 3 trial terminated early — ELI Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease

Phase 3 trial terminated early — ELI A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Ear

Phase 3 trial terminated early — Medtronic Thrombolysis Versus Primary Angioplasty for AMI in Elderly Patients

Phase 3 trial terminated early — AbbVie BOTOX Effects on Seizure Severity and Susceptibility

Phase 3 trial terminated early — Merck The Dublin Zepatier Study

Phase 3 trial terminated early — Merck A Study of MK0364 in Obese Patients (0364-014)

Phase 3 trial terminated early — PFIZER Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for Ac

Phase 3 trial terminated early — PFIZER Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photo

Phase 3 trial terminated early — PFIZER Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defin

Phase 3 trial terminated early — PFIZER Parecoxib In Post Surgery (Hemicolectomy) Pain

Phase 3 trial terminated early — GILEAD Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and

S&P 500 MINI — speculators net long (+2.8σ vs 52w mean) — contrarian bear signal

Bank OZK search volume spiked +32 pts — unusual interest

RH search volume spiked +28 pts — unusual interest

TAL Education Group search volume spiked +100 pts — unusual interest

ABBOTT LABORATORIES search volume spiked +92 pts — unusual interest

Strategy Inc search volume spiked +33 pts — unusual interest

Bank OZK search volume spiked +32 pts — unusual interest

TAL Education Group search volume spiked +100 pts — unusual interest

ABBOTT LABORATORIES search volume spiked +92 pts — unusual interest

Q1-2024: Missed consensus by 47.1% — EPS $-18.2 vs $-12.3725 estimate

Q3-2024: Missed consensus by 61.5% — EPS $-21.7 vs $-13.433 estimate

Q4-2023: Missed consensus by 197.6% — EPS $-168.35 vs $-56.56 estimate

Q1-2027: Beat consensus by 5.6% — EPS $0.14 vs $0.1326 estimate

Q1-2026: Beat consensus by 43.1% — EPS $0.26 vs $0.1817 estimate

Q2-2025: Beat consensus by 18.1% — EPS $0.66 vs $0.559 estimate

Q2-2025: Beat consensus by 13.7% — EPS $0.67 vs $0.5893 estimate

Q4-2025: Missed consensus by 7.5% — EPS $0.61 vs $0.6592 estimate

Q1-2026: Beat consensus by 11.7% — EPS $0.3 vs $0.2686 estimate

Q3-2025: Beat consensus by 15.8% — EPS $0.61 vs $0.5266 estimate

Q2-2012: Beat consensus by 126.3% — EPS $20 vs $-76.1532 estimate

Q1-2012: Missed consensus by 134.2% — EPS $-180 vs $-76.8468 estimate

Q4-2012: Missed consensus by 14.2% — EPS $140 vs $163.2 estimate

Q3-2012: Beat consensus by 586.3% — EPS $140 vs $20.4 estimate

Q4-2025: Missed consensus by 138.1% — EPS $-0.17 vs $-0.0714 estimate

Q2-2026: Missed consensus by 56.9% — EPS $-0.08 vs $-0.051 estimate

Q1-2026: Beat consensus by 34.6% — EPS $-0.04 vs $-0.0612 estimate

Q3-2025: Missed consensus by 929.4% — EPS $-0.21 vs $-0.0204 estimate

Q2-2025: Missed consensus by 7.6% — EPS $0.91 vs $0.9847 estimate

Q1-2026: Beat consensus by 9.5% — EPS $1.64 vs $1.4975 estimate

Q2-2025: Missed consensus by 14.4% — EPS $23.14 vs $27.0246 estimate

Q1-2026: Beat consensus by 66.0% — EPS $42.52 vs $25.6166 estimate

Q3-2025: Missed consensus by 161.9% — EPS $-9.96 vs $16.1024 estimate

Q4-2025: Missed consensus by 354.1% — EPS $-28.11406 vs $11.062 estimate

Q1-2026: Beat consensus by 5.2% — EPS $0.22 vs $0.2091 estimate

Q4-2025: Beat consensus by 42.0% — EPS $0.25 vs $0.1761 estimate

Q3-2026: Beat consensus by 30.3% — EPS $524.42805 vs $402.4668 estimate

Q2-2026: Beat consensus by 183.1% — EPS $437.38079 vs $154.5037 estimate

Q1-2026: Missed consensus by 113.2% — EPS $-104.41 vs $-48.9668 estimate

Q4-2026: Beat consensus by 25.8% — EPS $737.77 vs $586.3999 estimate

Q1-2026: Beat consensus by 24.4% — EPS $0.85 vs $0.6831 estimate

Q2-2025: Missed consensus by 11.0% — EPS $0.62 vs $0.6963 estimate

Q3-2025: Missed consensus by 19.9% — EPS $0.54 vs $0.6738 estimate

Q2-2025: Beat consensus by 7.9% — EPS $1.26 vs $1.1675 estimate

Q3-2025: Beat consensus by 10.0% — EPS $1.37 vs $1.2452 estimate

Q2-2019: Beat consensus by 35.1% — EPS $0.93 vs $0.6882 estimate

Q3-2019: Missed consensus by 36.3% — EPS $0.45 vs $0.7066 estimate

Q1-2020: Missed consensus by 246.7% — EPS $-0.42 vs $0.2863 estimate

Q4-2019: Missed consensus by 11.1% — EPS $0.3 vs $0.3376 estimate

Q4-2025: Beat consensus by 98.8% — EPS $-1.8 vs $-149.94 estimate

Q3-2025: Missed consensus by 42.4% — EPS $-318 vs $-223.38 estimate

Q1-2026: Missed consensus by 322.0% — EPS $-361.6 vs $-85.68 estimate

Q2-2025: Missed consensus by 114.9% — EPS $-4083 vs $-1900.26 estimate

Q4-2022: Missed consensus by 83.8% — EPS $-3 vs $-1.632 estimate

Q1-2023: Beat consensus by 47.2% — EPS $-1.4 vs $-2.652 estimate

Q3-2023: Missed consensus by 191.7% — EPS $-2.38 vs $-0.816 estimate

Q3-2025: Missed consensus by 96.1% — EPS $-0.02 vs $-0.0102 estimate

Q3-2025: Beat consensus by 296.1% — EPS $0.01 vs $-0.0051 estimate

Q1-2026: Missed consensus by 17.6% — EPS $-0.02 vs $-0.017 estimate

Q2-2025: Beat consensus by 296.1% — EPS $0.02 vs $-0.0102 estimate

Q4-2025: Beat consensus by 100.0% — EPS $0 vs $-0.0051 estimate

Q1-2026: Missed consensus by 366.9% — EPS $-1 vs $-0.2142 estimate

Q3-2025: Missed consensus by 86.9% — EPS $-0.61 vs $-0.3264 estimate

Q2-2025: Missed consensus by 59.6% — EPS $-2.36 vs $-1.479 estimate

Q4-2025: Missed consensus by 416.1% — EPS $-1.79 vs $-0.3468 estimate

Q1-2026: Missed consensus by 55.7% — EPS $-0.43 vs $-0.2761 estimate

Q3-2025: Beat consensus by 59.7% — EPS $0.2 vs $0.1252 estimate

Q4-2025: Missed consensus by 199.0% — EPS $-0.1 vs $0.101 estimate

Q2-2025: Missed consensus by 892.1% — EPS $-0.64 vs $0.0808 estimate

Q1-2023: Beat consensus by 52.6% — EPS $-4.95 vs $-10.4535 estimate

Q2-2023: Beat consensus by 52.1% — EPS $-5.445 vs $-11.3625 estimate

Q4-2022: Beat consensus by 26.7% — EPS $-9 vs $-12.2715 estimate

Q1-2024: Missed consensus by 372.2% — EPS $-1.24 vs $-0.2626 estimate

Q1-2026: Missed consensus by 694.1% — EPS $-0.06 vs $0.0101 estimate

Q2-2025: Missed consensus by 133.0% — EPS $-0.05 vs $0.1515 estimate

Q3-2025: Missed consensus by 57.5% — EPS $0.02 vs $0.0471 estimate

Q4-2025: Missed consensus by 937.1% — EPS $-0.55 vs $0.0657 estimate

Q3-2025: Missed consensus by 19.0% — EPS $0.37 vs $0.457 estimate

Q1-2026: Missed consensus by 5.3% — EPS $0.27 vs $0.285 estimate

Q1-2026: Missed consensus by 10.5% — EPS $0.09 vs $0.1006 estimate

Q2-2025: Beat consensus by 52.7% — EPS $0.3 vs $0.1964 estimate

Q4-2025: Missed consensus by 17.3% — EPS $0.21 vs $0.254 estimate

Q3-2024: Missed consensus by 20.3% — EPS $-24.55 vs $-20.4 estimate

Q2-2024: Missed consensus by 8.9% — EPS $-30 vs $-27.54 estimate

Q2-2025: Beat consensus by 30.7% — EPS $-0.41 vs $-0.5916 estimate

Q1-2024: Missed consensus by 12.6% — EPS $-31 vs $-27.54 estimate

Q3-2025: Beat consensus by 172.0% — EPS $0.34 vs $0.125 estimate

Q2-2025: Beat consensus by 16.6% — EPS $0.26 vs $0.2229 estimate

Q4-2025: Missed consensus by 4017.6% — EPS $-0.91 vs $-0.0221 estimate

Q1-2026: Missed consensus by 135.7% — EPS $-0.04 vs $0.1122 estimate

Q4-2025: Beat consensus by 13.4% — EPS $0.88 vs $0.7762 estimate

Q1-2026: Beat consensus by 14.1% — EPS $1.01 vs $0.8851 estimate

Q4-2025: Beat consensus by 100.0% — EPS $0 vs $-0.0101 estimate

Q3-2025: Missed consensus by 98.0% — EPS $-0.02 vs $-0.0101 estimate

Q2-2025: Beat consensus by 50.5% — EPS $-0.01 vs $-0.0202 estimate

Q2-2025: Beat consensus by 34.8% — EPS $-0.5 vs $-0.767 estimate

Q1-2026: Missed consensus by 89.7% — EPS $-1.86 vs $-0.9806 estimate

Q4-2025: Beat consensus by 220.5% — EPS $0.4 vs $-0.3319 estimate

Q3-2025: Beat consensus by 31.3% — EPS $0.28 vs $0.2132 estimate

Q4-2025: Beat consensus by 8.5% — EPS $0.24 vs $0.2213 estimate

Q1-2026: Beat consensus by 82.8% — EPS $0.23 vs $0.1258 estimate

Q2-2025: Beat consensus by 13.9% — EPS $0.11 vs $0.0966 estimate

Q4-2025: Beat consensus by 7.4% — EPS $0.49 vs $0.4563 estimate

Q2-2025: Beat consensus by 10.0% — EPS $0.59 vs $0.5365 estimate

Q3-2025: Missed consensus by 10.8% — EPS $0.47 vs $0.527 estimate

Q1-2026: Missed consensus by 5.6% — EPS $2.49 vs $2.637 estimate

Q4-2025: Missed consensus by 32.0% — EPS $-0.9 vs $-0.6818 estimate

Q1-2026: Beat consensus by 40.5% — EPS $-0.43 vs $-0.7222 estimate

Q3-2025: Beat consensus by 16.4% — EPS $-0.74 vs $-0.8854 estimate

Q2-2025: Beat consensus by 15.3% — EPS $-0.91 vs $-1.074 estimate

Q1-2026: Missed consensus by 117.3% — EPS $-0.03 vs $0.1734 estimate

Q4-2025: Beat consensus by 264.5% — EPS $0.26 vs $-0.1581 estimate

Q3-2025: Beat consensus by 1815.7% — EPS $0.7 vs $-0.0408 estimate

Q2-2025: Beat consensus by 295.5% — EPS $0.44 vs $-0.2251 estimate

Q2-2025: Beat consensus by 5.1% — EPS $1.64 vs $1.5599 estimate

Q1-2026: Beat consensus by 14.3% — EPS $1.16 vs $1.015 estimate

Q1-2026: Missed consensus by 186.7% — EPS $-0.32 vs $-0.1116 estimate

Q1-2026: Missed consensus by 117.5% — EPS $-1.71 vs $-0.7862 estimate

Q4-2025: Beat consensus by 85.4% — EPS $-0.09 vs $-0.6152 estimate

Q2-2025: Beat consensus by 44.2% — EPS $-0.41 vs $-0.7347 estimate

Q3-2025: Beat consensus by 88.6% — EPS $-0.08 vs $-0.7021 estimate

Q2-2026: Beat consensus by 28.4% — EPS $-0.45 vs $-0.6283 estimate

Q1-2026: Beat consensus by 38.2% — EPS $-0.43 vs $-0.6953 estimate

Q3-2026: Beat consensus by 146.7% — EPS $0.18 vs $-0.3856 estimate

Q4-2026: Missed consensus by 125.4% — EPS $-0.82 vs $-0.3638 estimate

Q1-2018: Missed consensus by 496.4% — EPS $-1295 vs $-217.15 estimate

Q1-2023: Beat consensus by 66.3% — EPS $-2335 vs $-6938.7 estimate

Q4-2018: Missed consensus by 87.6% — EPS $-1260 vs $-671.65 estimate

Q3-2018: Missed consensus by 4751.5% — EPS $-490 vs $-10.1 estimate

Q4-2024: Missed consensus by 10.3% — EPS $-0.25 vs $-0.2266 estimate

Q3-2024: Beat consensus by 56.4% — EPS $-0.22 vs $-0.5047 estimate

Q1-2026: Missed consensus by 7.0% — EPS $5.38 vs $5.7821 estimate

Q2-2025: Beat consensus by 12.7% — EPS $0.95 vs $0.8428 estimate

Q1-2026: Beat consensus by 16.0% — EPS $1.17 vs $1.0086 estimate

Q3-2025: Beat consensus by 24.3% — EPS $1.24 vs $0.9974 estimate

Q4-2025: Beat consensus by 5.1% — EPS $1.36 vs $1.2943 estimate

Q4-2025: Beat consensus by 10.9% — EPS $1.82 vs $1.6409 estimate

DXY -0.53% — dollar weakness signal

DXY -0.63% — dollar weakness signal